


Financials


If you would like more information on our audited financial accounts, please call us on 03 9289 9777. Here we provide a snapshot of our revenue sources in 2014-15.



Income sources 2014-2015


- Community Fundraising - General
- Community Fundraising - Afternoon Teal
- Sponsorship & Partners' Income
- Donations
- Other
 - Government grants
 - Merchandise
 - Bequests
 - Interest

Income growth 2008-2015



Fundraising

We rely on our fundraising community for a significant part of our income. The outstanding commitment and creativity of our fundraisers never ceases to amaze us. Please see below for a summary of our fundraising income.



Supporters

We would not be able to do the work we do without the dedicated support of our funding and major partners, corporate supporters, community partners and our valued pro-bono supporters.

Trusts and Foundations



Bequests

Estate of Mary-Rose Quinless Deceased

Major partners



Community Partners



Pro-bono suppliers



Project sponsors



In kind donations



A volunteer at the Chemmart MAN-icure launch



Rowen Craigie, Crown Resorts with Paula Benson, Ovarian Cancer Australia



(L-R) Martin Hall, Tim Scales, Sarah Cowling, Jason Millard and Jacqui Davison



Brisbane Heat players Nick Buchanan, Cameron Gannon, Mark Stekete and James Peirson with Katherine Brown and Ambassador Maria Hopes

Thank you

We have a proud and committed community of ambassadors, advocates and experts. These wonderful individuals contribute their time and expertise to our organisation and assist us to spread the word and ensure this disease gets the attention it so urgently needs.

Ambassadors

- Patricia Bailey
- Hon. Gai Brodtmann, MP
- Nicky Buckley
- Alice Burton
- Tracy Collins
- Sen. Sarah Hanson-Young
- Maria Hopes
- Hon Kelly O'Dwyer, MP
- Hon Sophie Cotsis, MLC
- Melissa Marsh
- Karen Martini
- Kate Ritchie
- Jane Stephens
- Cameron Smith
- Gary Sweet
- Kerry Vincent
- Madeleine West
- Monique Wright

Community ambassadors

- Rae Corbett
- Leanne French
- Tanya Hutchison
- Roz Kaldor-Aroni
- Alka Laji
- Dianne Leahy
- Sarah Madacki
- Rose Molloy
- Connie Nikolovski
- Jenny Owens
- Sylvia Penberthy
- Kirstie Rosie
- Lisa Smith
- Joanne Stefanovic
- Jane Tracey
- Kirsten Williams



Ambassador Monique Wright



Tracey Curro and Simon Leo



Ann-Maree Mulders and Christian Mulders



Our Medical and Research Advisory Group

Professor David Bowtell, Head, Cancer Genomics and Genetics, PI Australian Ovarian Cancer Study, Peter MacCallum Cancer Centre; **Karen Campbell**, Cancer Care Coordinator, Gynaecologic Oncology, Royal Hobart Hospital, Tasmania; **Professor Michael Friedlander**, Professor of Medicine, University of NSW and Director of Medical Oncology, Prince of Wales Hospital, Sydney; **Dr Gregory Gard**, Gynaecological Oncologist, Royal North Shore Hospital, Sydney; **Professor Neville F Hacker**, Professor of Gynaecological Oncology, Conjoint, University of New South Wales; **Dr Orla McNally**, Consultant Gynaecological Oncologist, Royal Women's Hospital, Melbourne; **Dr Linda Mileshkin**, Consultant Medical Oncologist, Peter MacCallum Cancer Centre and Mercy Hospital for Women, Melbourne; **Dr Gillian Mitchell**, Clinical Oncologist and Director, Familial Cancer Centre, Peter MacCallum Cancer Centre; **Dr Deborah Neesham**, Gynaecological Oncologist, Royal Women's Hospital, Melbourne; **Professor Andreas Obermair**, Queensland Centre for Gynaecological Cancer, University of Queensland – Medical School; **Associate Professor Lewis C Perrin**, Clinical Director, Mater Gynaecological Oncology Service, Queensland; **Professor Michael Quinn**, Department of Obstetrics and Gynaecology, University of Melbourne, Consultant Oncology/Dysplasia Unit, Royal Women's Hospital, Melbourne; **Dr Stuart Salfinger**, Gynaecologic Oncologist, King Edward Memorial Hospital, Perth; **Pauline Tanner**, Gynaecology Cancer Nurse Coordinator, WA Cancer and Palliative Care Network – Health Department of WA; **Dr Helen Zorbas**, CEO, Cancer Australia


Our research committee

Professor Michael Friedlander, Professor of Medicine, University of NSW and Director of Medical Oncology, Prince of Wales Hospital, Sydney; **Professor Ian Oliver**, Chief Executive Officer, Cancer Council Australia; **Associate Professor Penny Webb**, Group Leader, Gynaecological Cancers Group, Queensland Institute of Medical Research

Acknowledgements

Thank you to: Nicholas Andrews, Stephanie Alvarez, Alison Amos, Jan Antony and Mr D'Arcy (cover), Matt Benetti, Sue Bibby, Ilka Carapina, Anthony Cram, Annabel Davies, Alex Ding, Louise Doyle, Jane East, Katherine Elliott, Aayush Ganndi, Helen Gooden, Julie Hassard, Maggie Hill, Sheila Hirst, Sue Hollow, Tarnya Hotchkin, Samantha Hou, Emily James, Melissa Lau, Joanne Levy, Rina Lu, Debbie McCabe, Annie and Chris Mulders, Amanda Purdie, Vidya Rajamani, Rachel Shi, Jazba Singh, Rebecca Steele, Claire Sullivan, Ruth Thomas, Marion Webster, Bridget Whelan, Hilda Wong, Alex Woodland, Delon Xavier

Ovarian Cancer Australia
Limited ACN 097 394 593
Queen Victoria Women's Centre
Level 1, 210 Lonsdale Street
Melbourne, VIC 3000
www.ovariancancer.net.au
admin@ovariancancer.net.au
1300 660 334



Annual Highlights 2014-2015



Ovarian Cancer Australia



Message from the Chair

Ovarian Cancer Australia has undergone much change in the last year and we have marked several key milestones.

First and foremost, Ovarian Cancer Australia developed a National Action Plan for Ovarian Cancer Research. The plan provides a strategic blueprint for how Australia can best contribute to the global ovarian cancer research effort.

We acknowledge that the research environment is highly competitive and resources are finite. This highlights the need for a strategic approach that makes the best use of available human and fiscal resources. Our intent in developing the plan is to set an agreed direction and approach that will maximise our chances of success.

This past year we were also proud to host the then-Prime Minister, the Hon. Tony Abbott and the Opposition Leader, the Hon. Bill Shorten, at our Teal Ribbon Day breakfast at Parliament House in Canberra. The event launched our 25/25 Vision, which is our commitment to reducing the burden of ovarian cancer by 25% by 2025.

We will do this in three ways: improve awareness and early diagnosis; improve the identification of women at greatest risk; and provide increased access to effective treatments and care.

I would like to take this opportunity to thank former board member Stephanie Alvarez, for her valuable contribution to improving the lives of women living with ovarian cancer and their families. I would also like to welcome our three new board members: Tracey Curro, Sarah Adam-Gedge, and Jo-Ann Hicks, each of whom bring a wealth of experience, skills and expertise. And of course, I would like to thank continuing board members Simon Lee and Carolyn Reynolds for their guidance and support.

Ovarian Cancer Australia is stronger and more unified than ever, and we look forward to the future with renewed energy and focus.

Thank you.

Paula Benson
Chair



Message from the CEO

Since joining Ovarian Cancer Australia in May 2015, I have been overwhelmed by the enthusiasm and commitment of our vibrant community. Their support and engagement has buoyed myself and the staff, during what has been a year of transition for the organisation.

This year we have supported hundreds of women living with ovarian cancer and their families. Women across the country received a Resilience Kit after being diagnosed with ovarian cancer. Almost 700 requests were made to our support service for more information and referrals and we had record attendances of women, partners, friends and carers attending information forums.

I would like to take this opportunity to thank all the people who make Ovarian Cancer Australia what it is today: the staff, who work hard to achieve more positive outcomes for women living with ovarian cancer; the volunteers who contribute their time and skills to our organisation; the community and high profile ambassadors who help us spread the word about signs and symptoms and promote our services to the broader community; the sponsors who provide us with the financial and in-kind support to achieve our organisational goals; and our valued donors. Without you, we would not be able to offer our free support, awareness, advocacy and research programs to women living with ovarian cancer.

Finally, I would like to especially thank the Board of Directors for their stewardship, guidance, and support, and I look forward to continuing our work to help reduce the devastating impact of ovarian cancer on women and families, and to take action on behalf of all the women living with the disease. Together we can save lives and ensure that no woman with ovarian cancer walks alone.

Jane Hill
CEO

Support

We help women with ovarian cancer and their families, friends and carers to build resilience by connecting them to our community and by providing compassionate support programs, high-quality information and practical resources.

317

women received a Resilience Kit




356

women attended an in-person or telephone support group



329

women, partners, friends and carers attended an information session or forum



6

free information forums held nationally across Perth, Sydney and Melbourne



- Living with Cancer, Melbourne (Prostate Cancer Foundation Australia)
- Living with Cancer, Brisbane (Prostate Cancer Foundation Australia)
- What's on the horizon in research and treatment for ovarian cancer, Melbourne (BreaCan)
- Knowledge is Power, Melbourne
- Building Resilience, Sydney
- Building Resilience, Perth

749

requests were made for more information, support, and referrals through our 1300 line and email service



Awareness

We educate women and the community to recognise and act with urgency on the symptoms of ovarian cancer and to understand and access best practice diagnosis, treatment and support.

On Teal Ribbon Day, the then-Prime Minister, the Hon. Tony Abbott MP and the Opposition Leader, the Hon. Bill Shorten MP spoke at our parliamentary breakfast in Canberra. The event also marked the launch of our 25/25 Vision. Visit ovariancancer.net.au for more on the vision.



The Hon Tony Abbott MP, Paula Benson and the Hon Sussan Ley MP.



Ambassadors Gary Sweet and Cameron Smith at the Chemmart MAN-icure launch.

1062

media mentions during Ovarian Cancer Awareness Month

Seen by approximately

81,556,219

eyeballs!

Advocacy

We amplify the voices of women with ovarian cancer and provide expert views and evidence to demand action and funding to increase community awareness, improve equitable access to best practice diagnosis, treatment and support and increase the ovarian cancer research effort.



25/25 Vision

Our 25/25 Vision is aligned with the World Health Organisation 2013 World Cancer Declaration that calls for cancer societies around the world to collectively work on targets to reduce the burden of all cancers by 25% by 2025. For more on this, visit ovariancancer.net.au.

OUR VISION

25% improvement in survival rates of ovarian cancer by 2025

Research

We support excellence in ovarian cancer research and fund research that will improve the quality of life and survival for women with ovarian cancer.

Research funded by OCA

- The Australian Ovarian Cancer Study (with the Peter MacCallum Cancer Foundation): Led by Prof. David Bowtell (Peter MacCallum Cancer Centre). A collaborative program that collects bio-specimens, clinical and population data to develop a better understanding of ovarian cancer and new approaches to its treatment
- OCELI: An international consortium led by Prof. David Bowtell to develop novel and robust experimental models of ovarian cancer
- PhD Scholarship: Awarded to Dr Valerie Heong MBBS, (with the Walter and Eliza Hall Institute's Bev Gray Ovarian Cancer Scholarship). This project is targeted at improving precision medicine in High Grade Serous Ovarian Cancer. For an update please visit ovariancancer.net.au.

Consumer research by OCA

- Family history and genetic testing
- The importance of including patient wellbeing as a factor when determining the value of cancer care – the patient perspective.



\$1m

facilitated to support research underpinned by the National Action Plan for Ovarian Cancer Research

Public submissions to government inquiries and reviews

1. Senate Community Affairs Committee's Inquiry into the availability of new, innovative and specialist cancer drugs in Australia
2. Therapeutic Goods Administration Discussion paper on the Orphan drugs program released for public
3. Protocol Advisory Sub-Committee (PASC) of Medical Services Advisory Committee (MSAC): Application 1380 - Germline BRCA mutation testing to determine eligibility for olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer (including fallopian tube or primary peritoneal cancer) with high grade serous features or a high grade serous component.

Alliances and networks in which OCA actively participates

- World Ovarian Cancer Day
- Cancer Drugs Alliance
- Lymphoedema Action Alliance
- VPTAS (Victorian Patient Travel Access Scheme)
- Australian Cancer Consumer Network (ACCN)
- NSW Agency for Clinical Innovation – Gynaecology Oncology Network.

Other formal consumer roles

- Australia and New Zealand Gynaecology Oncology Group (ANZGOG)
- Cancer Australia.

OCA also represents the consumer voice in numerous discussion forums, workshops and roundtables, including:

- Medicines Australia: Biosimilars Roundtable
- Cancer Research Impact Evaluations Roundtable.

Research Participation

- OvQuest (ANZGOG)
- ReKindle (University of Sydney and Cancer Council NSW)
- The Ovarian Cancer Study (Centre for Community Driven Research).



Professor David Bowtell

People

Ovarian Cancer Australia has a small and dedicated board and staff that manages our support and information programs, awareness campaigns, research and advocacy.

Our Board



Paula Benson (Chair)



Sarah Adam-Gedge



Tracey Curro



Carolyn Reynolds

Absent: Jo-Ann Hicks, Simon Lee



Imogen Baratta, Manager, Communications and Awareness




Annemarie Ferguson, Coordinator, Support Programs



Louise Fewtrell, Fundraising and Communications Coordinator



Jane Hill, Chief Executive Officer



Adele Hornings, Administration Officer



Helen Li, Accounts Officer



Diana Liu, General Manager, Finance and Operations



Emma Robinson, Business Development Officer



Corinne Waddell, Coordinator, Support Programs

Absent: Dr Katherine Nielsen, Director of Research and Advocacy; Lea Rawlings, Perth Support Coordinator